Company Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States.
The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
It has a license agreement with city of hope national medical center and nationwide children’s hospital.
Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Manuel Litchman |
Contact Details
Address: 95 Sawyer Road, Suite 110 Waltham, Massachusetts 02453 United States | |
| Phone | 781 652 4500 |
| Website | mustangbio.com |
Stock Details
| Ticker Symbol | MBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001680048 |
| CUSIP Number | 62818Q302 |
| ISIN Number | US62818Q3020 |
| Employer ID | 47-3828760 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Manuel Litchman M.D. | President, Chief Executive Officer, Interim Chief Financial Officer and Director |
| Michael S. Weiss Esq., J.D. | Executive Chairman |
| Peter Carney | Controller and Interim Chief Accounting Officer |
| Greg Furrow M.S. | Chief Quality Officer |
| Robyn M. Hunter | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2026 | 10-K | Annual Report |
| Jan 5, 2026 | SCHEDULE 13D/A | Filing |
| Dec 23, 2025 | 8-K | Current Report |
| Dec 3, 2025 | DEF 14A | Other definitive proxy statements |
| Nov 7, 2025 | 10-Q | Quarterly Report |
| Oct 1, 2025 | SCHEDULE 13D/A | Filing |
| Sep 5, 2025 | 424B5 | Filing |
| Aug 12, 2025 | SCHEDULE 13G/A | Filing |
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Jul 9, 2025 | 8-K | Current Report |